This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2018 Nov 29;379(22):2173-2176.

doi: 10.1056/NEJMc1806941.

Mutagenesis in Norovirus in Response to Favipiravir Treatment

Affiliations

PMID: 30485769
DOI: 10.1056/NEJMc1806941

Free article

Case Reports

Mutagenesis in Norovirus in Response to Favipiravir Treatment

Christopher Ruis et al. N Engl J Med. 2018.

Free article

. 2018 Nov 29;379(22):2173-2176.

doi: 10.1056/NEJMc1806941.

Affiliations

¹ University College London, London, United Kingdom.
² Royal Free London NHS Foundation Trust, London, United Kingdom.

PMID: 30485769
DOI: 10.1056/NEJMc1806941

No abstract available

PubMed Disclaimer

Similar articles

Favipiravir elicits antiviral mutagenesis during virus replication in vivo.
Arias A, Thorne L, Goodfellow I. Arias A, et al. Elife. 2014 Oct 21;3:e03679. doi: 10.7554/eLife.03679. Elife. 2014. PMID: 25333492 Free PMC article.
Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis.
Thorne L, Arias A, Goodfellow I. Thorne L, et al. J Infect Dis. 2016 Feb 1;213 Suppl 1(Suppl 1):S27-31. doi: 10.1093/infdis/jiv280. J Infect Dis. 2016. PMID: 26744429 Free PMC article.
2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705.
Yu P, Wang Y, Li Y, Li Y, Miao Z, Peppelenbosch MP, Pan Q. Yu P, et al. Arch Virol. 2020 Nov;165(11):2605-2613. doi: 10.1007/s00705-020-04759-4. Epub 2020 Aug 8. Arch Virol. 2020. PMID: 32770483 Free PMC article.
Favipiravir and COVID-19: A Simplified Summary.
Ghasemnejad-Berenji M, Pashapour S. Ghasemnejad-Berenji M, et al. Drug Res (Stuttg). 2021 Mar;71(3):166-170. doi: 10.1055/a-1296-7935. Epub 2020 Nov 11. Drug Res (Stuttg). 2021. PMID: 33176367 Free PMC article. Review.
Chronic norovirus infection and common variable immunodeficiency.
Woodward J, Gkrania-Klotsas E, Kumararatne D. Woodward J, et al. Clin Exp Immunol. 2017 Jun;188(3):363-370. doi: 10.1111/cei.12884. Epub 2016 Nov 16. Clin Exp Immunol. 2017. PMID: 27753065 Free PMC article. Review.

See all similar articles

Cited by

Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
Kreins AY, Roux E, Pang J, Cheng I, Charles O, Roy S, Mohammed R, Owens S, Lowe DM, Brugha R, Williams R, Howley E, Best T, Davies EG, Worth A, Solas C, Standing JF, Goldstein RA, Rocha-Pereira J, Breuer J. Kreins AY, et al. Clin Immunol. 2024 Feb;259:109901. doi: 10.1016/j.clim.2024.109901. Epub 2024 Jan 12. Clin Immunol. 2024. PMID: 38218209 Free PMC article.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. Kaptein SJF, et al. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965. doi: 10.1073/pnas.2014441117. Epub 2020 Oct 9. Proc Natl Acad Sci U S A. 2020. PMID: 33037151 Free PMC article.
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
Shiraki K, Daikoku T. Shiraki K, et al. Pharmacol Ther. 2020 May;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22. Pharmacol Ther. 2020. PMID: 32097670 Free PMC article. Review.
Favipiravir in Therapy of Viral Infections.
Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Łagocka R, et al. J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273. J Clin Med. 2021. PMID: 33451007 Free PMC article. Review.
Variable rates of SARS-CoV-2 evolution in chronic infections.
Smith EW, Hamilton WL, Warne B, Walker ER, Jahun AS, Hosmillo M; ISARIC Consortium; Gupta RK, Goodfellow I, Gkrania-Klotsas E, Török ME, Illingworth CJR. Smith EW, et al. PLoS Pathog. 2025 Apr 28;21(4):e1013109. doi: 10.1371/journal.ppat.1013109. eCollection 2025 Apr. PLoS Pathog. 2025. PMID: 40294077 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information